SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation

Takuya Takeichi, … , Alan R. Brash, Masashi Akiyama


Find the latest version:

https://jci.me/130675/pdf
SDR9C7 catalyzes critical dehydrogenation of acylceramides for skin barrier formation

Takuya Takeichi,1 Tetsuya Hirabayashi,2 Yuki Miyasaka,3 Akane Kawamoto,4 Yusuke Okuno,5 Shijima Taguchi,6 Kana Tanahashi,1 Chiaki Murase,1 Hiroyuki Takama,7 Kosei Tanaka,8 William E. Boeglin,9 M. Wade Calcutt,10 Daisuke Watanabe,7 Michihiro Kono,1 Yoshinao Muro,1 Junko Ishikawa,4 Tamio Ohno,3 Alan R. Brash,9 and Masashi Akiyama1

1Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. 2Laboratory of Biomembrane, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. 3Division of Experimental Animals, Nagoya University Graduate School of Medicine, Nagoya, Japan. 4Biological Science Research Laboratories, Kao Corporation, Haga, Tochigi, Japan. 5Medical Genomics Center, Nagoya University Hospital, Nagoya, Japan. 6Division of Dermatology, Mitoyo General Hospital, Mitoyo, Ibaraki, Japan. 7Department of Dermatology, Aichi Medical University, Nagakute, Japan. 8Analytical Science Research Laboratories, Kao Corporation, Haga, Tochigi, Japan. 9Departments of Pharmacology and Biochemistry and 10Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee, USA.

The corneocyte lipid envelope, composed of covalently bound ceramides and fatty acids, is important to the integrity of the permeability barrier in the stratum corneum, and its absence is a prime structural defect in various skin diseases associated with defective skin barrier function. SDR9C7 encodes a short-chain dehydrogenase/reductase family 9C member 7 (SDR9C7) recently found mutated in ichthyosis. In a patient with SDR9C7 mutation and a mouse Sdr9C7–/– model, we show loss of covalent binding of epidermal ceramides to protein, a structural fault in the barrier. For reasons unresolved, protein binding requires lipoxygenase-catalyzed transformations of linoleic acid (18:2) esterified in ω-O-acylceramides. In Sdr9C7–/– epidermis, quantitative liquid chromatography–mass spectrometry (LC-MS) assays revealed almost complete loss of a species of ω-O-acylceramide esterified with linoleate-9,10-trans-epoxy-11E-13-ketone; other acylceramides related to the lipoxygenase pathway were in higher abundance. Recombinant SDR9C7 catalyzed NAD+-dependent dehydrogenation of linoleate 9,10-trans-epoxy-11E-13-alcohol to the corresponding 13-ketone, while ichthyosis mutants were inactive. We propose, therefore, that the critical requirement for lipoxygenases and SDR9C7 is in producing acylceramide containing the 9,10-epoxy-11E-13-ketone, a reactive moiety known for its nonenzymatic coupling to protein. This suggests a mechanism for coupling of ceramide to protein and provides important insights into skin barrier formation and pathogenesis.

Introduction

During the evolutionary process, when our ancestors left the aquatic environment, our integument developed a robust protective structure in the uppermost epidermis, the stratum corneum, and adjusted to the dry environment on the ground (1). The water barrier property of the stratum corneum is achieved by a fusion of lipids and proteins in the terminally differentiated cornocytes of the outer epidermis; the cell membrane is replaced by a coat of cross-linked proteins (the cornified cell envelope, CCE), and multilaminar lipid layers mainly composed of ceramides, cholesterol, and free fatty acids fill the space between the cells. Interfacing between the two on the outside surface of the CCE is a layer of covalently bound ceramides and fatty acids, the corneocyte lipid envelope (CLE) (2–4). The importance of the CLE to the integrity of the permeability barrier is known from its absence being a prime structural defect in many diseases of barrier function (4, 5). Among the epidermal ceramides, a key component is the ω-O-acylceramide CerEOS (esterified omega-hydroxy sphingosine). Defects in genes involved in biosynthesis of CerEOS or its processing to form the CLE result in the severe skin disorder autosomal recessive congenital ichthyosis (ARCI), characterized by dry skin, scaling, hyperkeratosis, and occasional erythroderma (6, 7). Moreover, alterations of epidermal lipid homeostasis, especially contents of CerEOS and other ceramides, are linked to atopic dermatitis (8). Thus, abnormal metabolism of epidermal ceramides underlies the pathogenesis of various skin diseases associated with defective skin barrier function.

The esterified component of CerEOS is the essential fatty acid linoleate (C18:2α6), linked through an ester bond to the eponymous fatty acid omega-hydroxy of EOS (9). Enzymatic oxidation of the linoleate ester in CerEOS by lipoxygenases (LOXs) is required for formation of the CLE (10, 11). Loss-of-function of 12R-lipoxygenase (12R-LOX) or epidermal lipoxygenase-3 (eLOX3) by gene mutations results in impaired permeability barrier function in patients with ARCI and in the corresponding knockout mice (12–14). The linoleate moiety of EOS cannot be replaced functionally by other fatty acids because they do not serve as a substrate for these epidermal LOXs. Accordingly, substitution of linoleate by oleate in CerEOS by prolonged intake of a diet lacking essential fatty acids impairs the normal formation of protein-bound ceramides (15), leading to an ichthyosis-like condition with dermatitis and increased transepidermal water loss (TEWL).

The mechanism in which the CLE is constituted from oxidized EOS on the surface of CCE has not been fully resolved. It has been
assumed that an unidentified esterase/lipase de-esterifies the oxidized linoleate in EOS to generate free ω-hydroxy ceramide (CerOS) for covalent binding to the CCE, thus forming the CLE, indicating an oxidation of the lipoxygenase products esterified in CerEOS. We clarify the biochemical function of SDR9C7 as catalyzing the oxidation of the ω-hydroxy ceramide to CerOS for covalent binding to the CCE, thus forming the CLE, the key to structural integrity of the permeability barrier of the epidermis.

**Results**

**Loss of the CLE in a patient with a recessive SDR9C7 mutation.** We identified a mutation in a patient with clear ARCI symptomatology (Figure 1A and Supplemental Figure 1A and B; supplemental material available online with this article; https://doi.org/10.1172/JCI130675DS1) as a rare homozygous missense mutation in the SDR9C7 gene (c.826C>T, p.Arg276Cys, rs755404310), as confirmed by Sanger sequencing (Supplemental Figure 1C); only 3 heterozygous carriers are reported so far in the gnomAD database (32). Whole-exome analysis showed no mutations in other genes heterozygous carriers are reported so far in the gnomAD database (17, 18). However, the transglutaminase(s) are not identified, and known gene knockouts do not exhibit the expected skin phenotype with absence of the CLE (19, 20). Furthermore, results inconsistent with the current line of thinking come from inactivation studies with PNPLA1, the gene that esterifies linoleate to CerOS, forming CerEOS (21–25). In PNPLA1-deficient mice or patients with mutations in the PNPLA1 gene, the CLE is almost absent even though CerOS and its glucosylated form are highly accumulated (22, 24, 25). This suggests that the prerequisite for lipoxygenase-catalyzed oxidation of CerEOS is not in order to facilitate de-esterification of the linoleate moiety and produce CerOS, but rather has a different functional role during formation of the CLE.

Herein we report what we believe are new insights into skin barrier formation stemming from an understanding of the activities of a recently described ARCI gene, SDR9C7. SDR9C7 encodes a short-chain dehydrogenase/reductase family 9C member 7 (SDR9C7) (26, 27), and is highly expressed in the epidermis (28). In 2016, 2 missense mutations in SDR9C7 were identified in patients with ARCI (29), and several more in 2018 (30). Our ultrastructural observations of the skin lesion of an ARCI patient with SDR9C7 mutations revealed disruption of the intercellular lipid layers in the stratum corneum (31). Now we have unraveled the pathomechanism and the enzymology of SDR9C7 through detailed structural and biochemical analyses in a patient’s epidermis, by development and characterization of an Sdr9c7 knockout mouse model, and by correlating these findings with the catalytic properties of the recombinant SDR9C7 enzyme. We clarify the biochemical function of SDR9C7 as catalyzing an oxidation of the lipoxygenase products esterified in CerEOS. This generates a chemically reactive epoxy-epsilon-enzyme that has the ability to bind directly to protein. This bypasses the need for removal of the oxidized linoleate from CerEOS prior to covalent binding. Thus, our results indicate an unsuspected role of SDR9C7 in facilitating covalent binding of oxidized acylceramide to CCE proteins, thus forming the CLE, the key to structural integrity of the permeability barrier of the epidermis.

A skin biopsy specimen showed compact hyperkeratosis with a normal-appearing granular layer (Figure 1B). Immunohistochemical analysis showed low immunoreactivity for SDR9C7 in the stratum corneum and granulosum in a lesional skin sample from the patient compared with control (Figure 1C), suggesting that SDR9C7 with the R276C mutation results either in lower transcription or in an unstable protein that is degraded rapidly in the differentiated keratinocytes. Lipids in the tape-stripped skin samples from the patient, her unaffected parents, and normal controls were assessed by LC-MS and thin-layer chromatography. Although the overall effects of bi-allelic mutation on the levels of total ceramide, nonesterified ceramides, and free fatty acids were small, notably, the EOS levels in the patient’s epidermis are 2.8-fold elevated compared with normal controls (Figure 1, D–G, and Supplemental Tables 1–8). Mechanistically tied to this increase in CerEOS is the almost complete loss of the covalently bound ceramides CerOS and CerOH in the patient (Figure 1, H and I; Table 1 and Table 2). These results suggest that functional SDR9C7 is required for formation of the fundamental structural component of the epidermal permeability barrier, the CLE, from its main precursor CerEOS.

**Sdr9c7–/– mice recapitulate aspects of the human ichthyosis.** To gain deeper insight into the function of Sdr9c7 in vivo, we used a CRISPR-Cas9 gene-targeting approach to generate Sdr9c7 knockout mice. The frameshift mutation in the Sdr9c7 gene (Supplemental Figure 2, A and B) likely leads to nonsense-mediated decay of the mRNA transcript (Supplemental Figure 3E). The expression of Sdr9c7 protein in Sdr9c7–/– epidermis was also not detected by immunohistochemistry with a polyclonal antibody to the C-terminal region of Sdr9c7 (Supplemental Figure 2C). Offspring from heterozygote intercrosses were born at the expected Mendelian ratio (Supplemental Table 9). Although the Sdr9c7–/– mice were healthy and indistinguishable from WT mice, newborn Sdr9c7–/– pups had dry skin (Figure 2A) and died within 5 hours after birth. The Sdr9c7–/– pups were lighter at birth than the Sdr9c7+/– and Sdr9c7+/- genotypes (about 70%, p < 0.01), and they lost additional weight over 5 hours (Supplemental Figure 2D). In accordance with this steep weight reduction, TEWL was markedly higher in the Sdr9c7–/– newborns (Figure 2B), indicating a severe defect of the inside-out barrier in the null mice. This was supported by a toluidine blue exclusion assay in which the WT littermates excluded dye, whereas Sdr9c7–/– pups showed robust dye penetration into the skin (Figure 2C).

As expected, histological analysis revealed that Sdr9c7–/– mice had a clear basket weave-like structure segregated by interspaces, indicative of the presence of lipid lamellae (Figure 2D, left). In contrast, Sdr9c7–/– mice exhibited a tightly packed structure in the stratum corneum, a reduced number of keratohyaline granules in the uppermost stratum granulosum, and epidermal hyperplasia (Figure 2D, right), which is an adaptive response to barrier disruption. These findings are consistent with histological features in the skin sample from the ARCI patient with the SDR9C7 mutation (Figure 1B). Ultrastructurally, in the stratum corneum of Sdr9c7–/– mice, CLE was defective or completely lacking, compared with the intact CLE in the stratum corneum of WT mice (Figure 2, E and F, and Supplemental Figure 2E). The absence of protein products from Sdr9c7 in the skin of Sdr9c7–/– mice was confirmed by immunohistochemistry (Supplemental Figure 2C). Moreover, LC-MS analysis of the covalently bound CerOS from the protein pellets from Sdr9c7+/- and Sdr9c7–/– skin samples revealed a nearly
90% reduction of bound CerOS in the Sdr9c7 knockout epidermis (Figure 2G). These phenotypes, which have been commonly observed in mutant mice with disruption of genes associated with ARCI caused by skin barrier defects, indicate that Sdr9c7 is required for epidermal permeability barrier function.

Gene expression profile in the skin of Sdr9c7−/− mice. We performed microarray gene profiling using skins of newborn Sdr9c7+/+ and Sdr9c7−/− mice, and focused on differentially expressed genes (DEGs) associated with the following key words related to skin barrier function and ichthyoses: ichthyosis, acylceramide metabolism,
retinoid metabolism, steroid metabolism, and keratinocyte differentiation. There was no significant change in the expression of most genes related to the retinoid metabolism, steroid metabolism, and keratinocyte differentiation (Supplemental Figure 3D). Real-time quantitative PCR (qPCR) confirmed the slightly diminished expression of Alox3 in the Sdr9c7–/– skin relative to the WT skin, whereas mRNA expression levels of the Alox12b, Tgm1, and Lor were similar between the 2 genotypes (Supplemental Figure 3E). Additionally, the Sdr9c7–/– skin showed a marked reduction in expression of Irf4, a transcription factor required for functional development of type 1 regulatory T cells (33), and interpreted as evidence of secondary and global disruptions in epidermal functionality.

We also compared gene expression profiles between mouse lines deficient in Sdr9c7 and Pnplai; the latter selectively utilizes linoleic acid for acylceramide biosynthesis, and loss of this activity causes severe epidermal barrier defects (22). Overall, the gene expression changes in the skin from Sdr9c7–/– mice were smaller compared with Pnplai–/– mice (Supplemental Figure 3, A and B). Venn diagrams and heatmaps indicated that the number of overlapping DEGs in these 2 knockout lines was very limited (Supplemental Figures 8–15), and establishing the chemical structure of the prominent new peak in the Sdr9c7–/– epidermis. The main species of the new polar product showed a MH+ ion at m/z 1117, compatible with CerEOS containing a C34:1 ω-hydroxy–ultra long-chain fatty acid (ω-OH-ULCFA) esterified with a trihydroxy-C18:1 fatty acid (Figure 3C). This was confirmed by negative ion detection of m/z 329, corresponding to the mass of a trihydroxy-C18:1 fatty acid (Supplemental Figure 12), as well as positive ion detection of product ions characteristic of a C18:1 sphingosine moiety (Supplemental Figure 13) (34). Thus, the intense new product in the Sdr9c7 knockout epidermis was identified as CerEOS esterified with trihydroxy-C18:1 (EOS-triol). Moreover, a degraded derivative of EOS-triol lacking the sphingosine moiety, namely ω-OH-ULCFA esterified with C18:1-triol was also detected in the Sdr9c7–/– epidermis (Supplemental Figures 8 and 9).

To further explore the influence of Sdr9c7 deficiency on the lipoxygenase pathway derivatives of CerEOS, epidermal lipids from WT and Sdr9c7–/– mice were analyzed by quantitative LC-MS (Figure 4, A and B). The most striking finding, confirming the results above, is the astonishing 100-fold elevation over WT of EOS-triol in the Sdr9c7–/– epidermis (Figure 4, A and B).

### Table 1. Amounts of covalently bound ceramides in the stratum corneum of the upper arm from the patient and her parents: comparison with those of normal controls

<table>
<thead>
<tr>
<th>Total (μg/μg protein)</th>
<th>Patient (p.Arg276Cys homo)</th>
<th>Father (p.Arg276Cys hetero)</th>
<th>Mother (p.Arg276Cys hetero)</th>
<th>Controls, n = 8 (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CerOH</td>
<td>0.18</td>
<td>1.07</td>
<td>1.90</td>
<td>1.90 ± 0.44</td>
</tr>
<tr>
<td>CerOS</td>
<td>0.12</td>
<td>0.75</td>
<td>1.21</td>
<td>0.88 ± 0.18</td>
</tr>
</tbody>
</table>

### Table 2. Amounts of covalently bound ceramides in the stratum corneum of the forearm from the patient and her parents: comparison with those of normal controls

<table>
<thead>
<tr>
<th>Total (μg/μg protein)</th>
<th>Patient (p.Arg276Cys homo)</th>
<th>Father (p.Arg276Cys hetero)</th>
<th>Mother (p.Arg276Cys hetero)</th>
<th>Controls, n = 8 (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CerOH</td>
<td>0.22</td>
<td>0.61</td>
<td>1.48</td>
<td>1.55 ± 0.48</td>
</tr>
<tr>
<td>CerOS</td>
<td>0.13</td>
<td>0.34</td>
<td>0.77</td>
<td>0.68 ± 0.26</td>
</tr>
</tbody>
</table>
The quantitative LC-MS analysis identified this hugely elevated linoleate-derived triol as specifically the 9R,10S,13R-trihydroxy isomer (Figure 4C), the one formed selectively via the consecutive actions of 12R-LOX, eLOX3, and epoxide hydrolase (34, 35).

The most prominent oxidized linoleate esterified to CerEOS in the WT epidermis is the epoxy-ketone (Figure 4, A and B), and this 9,10-epoxy-11E-13-ketone is largely eliminated in the Sdr9c7–/– epidermis (only 7% of WT) (Figure 4, A, B, and D). On account of SDR9C7 being a member of the short-chain dehydrogenase/reductase family, its expected direct activity is in oxidation of lipids containing an alcohol group adjacent to a double bond, producing the corresponding allylic ketone. This activity equates with oxidation of the 12R-LOX/eLOX3 product 9,10-epoxy-11E-13-alcohol into the 9,10-epoxy-11E-13-ketone, and is consistent with drastic reduction of the epoxy-ketone in the Sdr9c7 knockout epidermis. In further support of this scenario, the knockout epidermis contains 10-fold higher abundance of the putative Sdr9c7 substrate, the 9,10-epoxy-11E-13-alcohol (Epoxy-OH in Figure 4, A and B). 9-HODE, the further upstream pathway product, is also elevated in the knockout (Figure 4, A and B). And as presented earlier, unmetabolized CerEOS accumulated in the epidermis of the ichthyosis patient with the SDR9C7 mutation (Figure 1). Taken together, the ceramide analyses point to the primary catalytic activity of SDR9C7 being the oxidation of epoxy-alcohol esterified in CerEOS to the corresponding epoxy-ketone.

As indicated in the Introduction, the ultimate structural defect in the knockout of many ARCI genes is a lack of covalently bound ceramides in the epidermal barrier. For example, this is a proven consequence in deficiencies of PNPLA1, 12R-LOX, eLOX3, and other ARCI genes (4, 5). And, as indicated earlier, analysis of the covalently bound CerEOS are significantly reduced in the epidermis of Sdr9c7–/– (KO) mice compared with that of Sdr9c7+/+ (WT) mice (mean ± SEM, n = 3 or 4, Student’s t test, P < 0.001).
bound CerOS from the protein pellets from Sdr9c7+/+ and Sdr9c7−/− skin samples revealed a 90% reduction of CerOS in the Sdr9c7 knockout epidermis (Figure 2G). Accordingly, we can conclude that the biochemical changes resulting from an absence of catalytically active SDR9C7 lead to a failure to produce covalently bound ceramides, with the resulting physiological defects in the skin barrier.

SDR9C7 is a dehydrogenase on epidermal lipoxygenase products. To establish the catalytic capabilities of SDR9C7, the recombinant human enzyme and the 2 naturally occurring mutants identified in ARCI patients were produced in insect cells and partially purified using FLAG-tagged affinity columns. The missense mutation in ARCI patients were produced in insect cells and partially purified using FLAG-tagged affinity columns. The missense mutation identified in the new patient, R276C, gives the same sized protein band as WT on SDS-PAGE (~33 kDa), and the nonsense mutation, identified in the new patient, R220*, with a premature stop codon, results in an approximately 25 kDa protein band (Supplemental Figure 16, A–D). The amino acid conversion of the 1 mM NAD+ cosubstrate to NADH. The SDR9C7-catalyzed oxidation of 9-HODE-Me, 13-HODE-Me, RRR-EpOH-Me, and RSR-EpOH-Me, and RRR-Triol-Me were similar, each attaining an increase in 340 nm absorbance of NADH of approximately 0.06 AU in 10 minutes at room temperature, representing 10% conversion of the 1 mM NAD+ cosubstrate to NADH. The SDR9C7 oxidation products were extracted and analyzed by HPLC-UV in comparison to authentic standards, thus establishing that the HOE-Me substrates are converted to the corresponding 9- or 13-ketone, and the RRR-EpOH-Me converted purely to the corresponding 13-ketone (Figure 5, B and C).

The chemical structure of prostaglandins includes a 13E-15-hydroxy moiety equivalent to the 11E-13-hydroxyl on the linoleate substrates. Furthermore, prostaglandins are metabolized in vivo by 15-hydroxyprostaglandin dehydrogenase, an SDR family member (SDR36C1) that converts the allylic 15-hydroxyl to a ketone. However, using a sensitive HPLC-UV assay, no activity was detectable with SDR9C7 and PGE, or PGE, methyl ester, indicating a distinct substrate specificity that can distinguish the similar ω6

Figure 3. Epidermal accumulation of EOS-triol in Sdr9c7 null mice. (A) Representative TLC analysis of lipids extracted from Sdr9c7+/+, Sdr9c7−/−, and Sdr9c7−/− epidermis. Sdr9c7−/− mice show the appearance of a major new polar lipid running between CerOS and Glc-CerEOS. In all 3 Sdr9c7 genotypes, note the normal appearance of CerEOS, which is absent in the Pnpla1 knockout (right lane). The experiment was repeated 4 times with consistent results. (B) Normal-phase LC-MS analysis of WT and knockout Sdr9c7 epidermal lipids. The chromatograms show the total ion current profile (m/z 950–1350) of LC-MS analysis of MeOH/CHCl3 epidermal extracts of WT (top panel, blue profile), and Sdr9c7−/− (bottom panel, red profile) using an Advantage 5-μm silica column (250 × 4.6 mm) run with gradient elution of hexane/isopropanol/glacial acetic acid (95:5:0.1) to hexane/isopropanol/glacial acetic acid (75:25:0.1) over 30 minutes using a Waters Alliance 2690 HPLC system coupled to a TSQ Vantage mass spectrometer. Note the prominent peak at approximately 20.5 minutes in the knockout, which is undetectable using this methodology in the WT. (C) Partial mass spectrum (m/z 1000–1150) of the 20.5-minute peak, with ion fragments identifying the product as CerEOS containing esterified trihydroxy-C18:1 fatty acid (EOS-triol).
allylic hydroxyls of prostaglandins and the linoleate 12R-LOX/eLOX3 metabolites. Finally, *E. coli* lysates of expressed SDR9C7 were reported to show weak NADH-dependent reduction of all-trans-retinal to all-trans-retinol (26). With our partially purified SDR9C7, there was no detectable NAD+ or NADH-dependent inter-conversion of all-trans-retinal and all-trans-retinol, whereas side-by-side incubations with RRR-EpOH-Me showed more than 50% transformation to the 13-ketone.

**Discussion**

**SDR9C7 is essential for epidermal barrier formation.** Clinical observations reinforced by the phenotype of the knockout mouse confirm the physiological functioning of SDR9C7 as crucial for formation of the epidermal permeability barrier. Human patients show the typical ARCI features of dry skin, scaling, and hyperkeratosis. In our mouse knockout model, the skin of the Sdr9c7–/– pups failed to exclude toluidine dye and there was loss of body weight associated with TEWL. Analyses of the epidermis of both the patient and the knockout mouse revealed a severe depletion of the covalently bound ceramides, consistent with ultrastructural studies in the human patient showing failure to form the CLE. Significantly, the present mutation we identified in the patient (p.Arg276Cys) resulted not only in loss of catalytic activity, as we demonstrated with the recombinant enzyme, but also the mutation is associated with reduced expression in the stratum corneum and the stratum granulosum (Figure 1C). This reduced expression was observed in some previous reports (29, 31), although it is not a universal feature of ARCI associated with SDR9C7 mutations (30).

**The pathway of ceramide oxidations in the epidermis.** Based on the LC-MS analysis of oxidized cerinoles in the epidermal ceramides, together with the catalytic activities we identified for SDR9C7, we conclude that the oxidative pathways in forming the epidermal barrier proceed via LOX-catalyzed transformation of CerEOS followed by SDR9C7-catalyzed formation of an epoxy-enone derivative. As expanded on below, we propose that the chemical reactivity of the epoxy-enone with protein holds the key to the role of the enzymatic pathway in forming the CLE. Figure 6A illustrates the normal oxidative pathway, and Figure 6B is intended to convey a visual impression of the alterations when SDR9C7 is blocked or absent. As established by LC-MS analysis of the oxidized ceramides, loss of SDR9C7 leads to accumulation of the pathway precursors (CerEOS, CerEOS-9-HODE, CerEOS-epoxy-alcohol) as well as a huge accumulation of CerEOS-triol as

---

**Figure 4. Quantitative LC-MS of oxidized linoleates esterified in WT and Sdr9c7−/− (Sdr9c7 KO) epidermis.** (A) Quantitation of 9-HODE, 9,10-trans-11E-13-ketone (Epoxy-ketone), 9,10-dihydroxy-11E-13-ketone (DIOH-ketone), and 9R,10S,13R-trihydroxy-linoleate (Triol RSR). (B) The same data from A, shown on scale with the Sdr9c7 knockout levels of Triol RSR. Results are expressed in ng/mg epidermis (mean ± SEM, n = 8, P < 0.001 for all pairs of WT compared with knockout, except for DIOH-ketone [n = 4, P = 0.05]). (C) LC-MS ion chromatograms illustrating analysis of linoleate triols: top panel, blue trace shows the triols in WT; middle panel, red trace shows the 100-fold higher levels of Triol RSR in Sdr9c7−/− compared with WT; lower panel, black trace shows the d4 triol internal standard used for quantitation. (D) LC-MS ion chromatograms illustrating analysis of the Epoxy-ketone, with WT (top, blue trace), knockout (middle, red trace), and d3 epoxy-ketone internal standard (lower, black trace). Samples are analyzed with the 13-ketone derivatized to a 13-methoxime, which gives syn and anti isomers (the 2 peaks in the d0 channel); the d3 internal standard was added as a single methoxime isomer, hence only one peak appears in the lower chromatogram. Oxidized lipids were isolated for LC-MS analysis as described in the Supplemental Data.
Schiff base (Figure 6E) (2, 36, 37). Although both such transformations are reversible, they could promote a close association of ceramide and protein for subsequent irreversible binding. In fact, an earlier study of LC-MS analyses of mouse epidermis detected the reversible protein binding of CerEOS-epoxy-enone (10). Addition of the epoxide group in conjugation with the enone moiety (epoxy-enone) greatly enhances the reactivity with protein. Indeed, the very linoleate 9,10-epoxy-11E-13-keto-octadecenoate as formed through the LOX/SDR9C7 pathway is a well-established model compound used to define the chemistry of lipid-protein binding (38, 39). It is shown to form pyrrole and furan derivatives in irreversible covalent reaction with lysine and other protein residues (Figure 6E). Thus, we envisage the key role for SDR9C7 in forming a bypass route when SDR9C7 is blocked. The normal route involving SDR9C7 forms CerEOS-epoxy-enone.

A new hypothesis for covalent binding via the chemical reactivity of CerEOS-epoxy-enone. We propose that the ultimate chemical or biochemical role of the SDR9C7-mediated transformation to CerEOS-epoxy-enone is to facilitate ceramide binding to the proteins of the CCE and thus initiate formation of the CLE (Figure 6C). In terms of the chemical reactivity of the epoxy-enone moiety created by SDR9C7, there is ample literature precedent to support a role in protein binding. A plain α/β-unsaturated ketone (simply an enone) is reactive via Michael addition to cysteine, histidine, and lysine amino acid residues (Figure 6D) (2, 36, 37). Furthermore, reaction with amino groups will link the fatty acid to protein as a Schiff base (Figure 6E) (2, 36, 37). Although both such transformations are reversible, they could promote a close association of ceramide and protein for subsequent irreversible binding. In fact, an earlier study of LC-MS analyses of mouse epidermis detected the reversible protein binding of CerEOS-epoxy-enone (10). Addition of the epoxide group in conjugation with the enone moiety (epoxy-enone) greatly enhances the reactivity with protein. Indeed, the very linoleate 9,10-epoxy-11E-13-keto-octadecenoate as formed through the LOX/SDR9C7 pathway is a well-established model compound used to define the chemistry of lipid-protein binding (38, 39). It is shown to form pyrrole and furan derivatives in irreversible covalent reaction with lysine and other protein residues (Figure 6E). Thus, we envisage the key role for SDR9C7 in forming
a biomarker of barrier function (8). According to our new concept, there is no requirement for the unidentified missing esterase (5, 13) to remove the oxidized linoleate and provide free CerOS for coupling to protein. Also, for this proposed early stage of forming the covalently bound ceramides, the enzyme transglutaminase is not required for covalent binding.

Slightly as an aside, although of indirect relevance, there are several ARCI genes whose inactivation leads to accumulation of CerOS, the ceramide with the free omega-hydroxyl that can bind to protein glutamate residues via ester linkage (17, 40). Yet in the case of inactivation of PNPLA1 or CGI-58 (ABHD5) (22, 24, 41), a prime structural defect in the barrier is loss of the CLE. One might reasonably question why there is accumulation of what is generally considered to be the main substrate for covalent binding (CerOS), yet formation of the CLE is impaired? Possibly this could be explained by the direct binding of CerOS not being the major pathway involved in initiation of covalent protein binding.

A further concept stemming from the huge accumulation of CerEOS-triol in the Sdr9c7 knockout is that normally there is a sub-CerEOS-epoxy-enone for covalent reaction with protein and leading to formation of the CLE (Figure 7).

**Points in favor of the new hypothesis.** For the last several years, a credible hypothesis on the functioning of the lipoxygenase pathway has foreseen a role for the LOX products including EOS-triol, based on their high polarity. This was considered to facilitate esterase-catalyzed cleavage of the oxidized linoleate, thus providing free CerOS as a substrate for covalent coupling to protein (10, 13, 34). However, the massive accumulation of CerEOS-triol in the Sdr9c7 knockout animals suggests that an esterase-catalyzed cleavage of the linoleate-triol from the ceramide is not the functional pathway. If it were, the release of nonesterified linoleate-triol would be predicted, whereas in fact, judging from the huge accumulation of CerEOS-triol, it appears that ester-catalyzed release of free triol is not operative.

This conclusion concurs with the very low levels of free linoleate triol measured in normal human and murine epidermis (34), albeit modestly elevated levels (<0.2 pg/μg protein) are reported in association with atopic dermatitis and are suggested as a biomarker of barrier function (8). According to our new concept, there is no requirement for the unidentified missing esterase (5, 13) to remove the oxidized linoleate and provide free CerOS for coupling to protein. Also, for this proposed early stage of forming the covalently bound ceramides, the enzyme transglutaminase is not required for covalent binding.

Slightly as an aside, although of indirect relevance, there are several ARCI genes whose inactivation leads to accumulation of CerOS, the ceramide with the free omega-hydroxylinoleate that can bind to protein glutamate residues via ester linkage (17, 40). Yet in the case of inactivation of PNPLA1 or CGI-58 (ABHD5) (22, 24, 41), a prime structural defect in the barrier is loss of the CLE. One might reasonably question why there is accumulation of what is generally considered to be the main substrate for covalent binding (CerOS), yet formation of the CLE is impaired? Possibly this could be explained by the direct binding of CerOS not being the major pathway involved in initiation of covalent protein binding.

A further concept stemming from the huge accumulation of CerEOS-triol in the Sdr9c7 knockout is that normally there is a sub-
stantial flux through the pathway in the WT epidermis. It may be that in the normal epidermis the route to CerEOS-triol serves as a fine-tuning valve in regulating the production of CerEOS-epoxy-enone.

Assessing the evidence for ceramide binding in the CLE via ester bonds to glutamate. In a classic and well-cited paper by Marekov and Steinert (40), the corneocyte envelopes from human foreskin tissue were purified, proteolytically digested, and the resulting lipoprotein fragments arising from the covalently bound CLE were analyzed by LC-MS. In the lipopeptides isolated, the lipid component is within the correct range to include CerOS, and too light in mass to be CerEOS (of mass range ~950–1100 when the lipid component is within the correct range to include CerOS, and too light in mass to be CerEOS (of mass range ~950–1100 when linoleate or oxidized linoleate is the ester-linked fatty acid). In support of the findings, Nemes and Steinert showed that, in vitro, transglutaminase can form an ester linkage between a CerOS analogue and glutamate residues in involucrin protein (17). Together, the 2 studies represent impressive technical accomplishments and establish that the direct linkage of CerOS to protein via an ester bond to glutamate is at least a significant component of the CLE.

To the best of our knowledge, the Marekov and Steinert paper (40) is the only study reporting directly on modes of ceramide-protein linkage in the epidermis. To what extent does this pioneering work leave open the possibilities for additional modes of lipoprotein interaction and covalent binding? For a start, the identified lipoprotein fragments accounted for about 20% of the total estimated ceramide binding to the human foreskin CCE (40), leaving space for additional modes and mechanisms. Second, involucrin, the primary CLE protein involved in the identified lipopeptides, is not itself essential for barrier function (there is considerable redundancy in regard to CCE proteins) (42, 43), suggesting the measured lipopeptides do not in themselves represent vital components of the barrier. Third, all further studies on the topic of covalent binding of ceramide to the CCE used mild alkaline hydrolysis to release the free ceramide, an approach that cannot distinguish between the release of free CerOS from ester bond to glutamate (as universally interpreted), to the release of the same free CerOS from bonding induced via covalent reaction with CerEOS-epoxy-enone (Figure 6).

Summing up. In the early stages of construction of the CCE and covalent binding of ceramide, nucleation of the incipient structures is focused around desmosomes (44), and it is at this stage that we foresee a critical role for covalent reaction of CerEOS-epoxy-enone to initiate lipoprotein bonding. Indeed, synthesis of the epoxy-enone moiety itself must occur in viable cells with availability of NAD⁺ cofactor, a surmise that matches with the recent conclusion that 12R-LOX and eLOX3 create the oxygenated CerEOS in viable cells at the relatively early developmental stages of creation of the barrier (16). The reactivity of the epoxy-enone moiety can initiate binding via Michael addition, and this could become irreversible through pyrrole formation as established over 2 decades ago in model studies using the methyl ester of linoleate 9,10-epoxy-11 trans-ke- tone (38, 39). While it will be a considerable technical challenge to detect these formative structures, our work identifies specific possibilities and sets new goals for future barrier-related investigations.
Targeted disruption of the Sdr9c7 gene on a C57BL/6J background was carried out by using the CRISPR/Cas9 method as previously described (46). The CRISPR RNA (crRNA, 5′-CAACAGGTGGTCTG-GCCAACT-3′) that targets exon 1 was designed using the CRISPOR website (47). The designed crRNA and trans-activating crRNA (tracrRNA) (Genome CraftType CT, FASMAC) and Cas9 protein (New England Biolabs) were mixed and incubated at 37°C for 20 minutes to form a ribonucleoprotein complex (RNP). We initially hypothesized that pathogenic biallelic mutations in Sdr9c7 in mice might result in embryonic lethality. Therefore, we mixed the single-stranded donor oligonucleotide (ssODN) with RNP preparation to generate found-er mice carrying heterozygous knockout alleles of the Sdr9c7 gene. The ssODN (5′-TCTCTACATGGCCTGTGACTCCGGCTTTGGGAAATCGTGTTGCCAAACAACTGTGTTGATAGGGAGTGCCTGTGCT-3′) was designed to include a silent (synonymous) c.117C>T mutation to avoid cleavage by Cas9 and was obtained from FASMAC. The final concentrations of components in RNP preparation with ssODN were 8 μg guide RNA (crRNA + tracrRNA), 200 ng/μL Cas9 protein, and 250 ng/μL ssODN. The mixture was electroporated into zygotes using a NEPA 21 electroporator (NEPA GENE Co. Ltd.) and the embryos were transferred into the oviductal ampulla of pseudopregnant Institute of Cancer Research mice.

For sequencing and genotyping, genomic DNAs were extracted using KAPA Express Extract (Kapa Biosystems) from the pinna and tail of the offspring and used for PCR amplification. The target region by the Cas9 nuclease was amplified by using a GoTaq Green Master mix (Promega) and a primer pair (5′-CTGTGTCAGCTGACAACTGCTTCC-3′ and 5′-GACATCTAGGAGGAAGGTCTGAC-3′). Mutations in the Sdr9c7 gene in offspring were confirmed by Sanger sequencing of the PCR products using Eurofins DNA sequence service (Eurofins Genomics) (Supplemental Figure 2B). Potential off-target sequencing of the PCR products using Eurofins DNA sequence service (Eurofins Genomics) (Supplemental Methods). The LC-MS analyses used an LTQ linear ion trap mass spectrometer (Thermo-Electron) equipped with an Ion Max APCI-MS source and recording positive ions (m/z 700–900) in full scan mode, and a Phenomenex Luna 5 μm silica column with a solvent of hexane/isopropanol/glacial acetic acid, 90:10:0.1 (vol/vol) at a flow rate of 0.6 mL/min, with retention time for CerOS of approximately 4 minutes.

Preparation of oxidized linoleates and deuterated internal standards. Hydroxy-oxadecadienoates (HODEs), linoleate epoxy-alcohols, and linoleate triols were prepared as described (49, 50). The corresponding 13-ketones of the epoxy-alcohol and triol were prepared as described in detail in Supplemental Methods. All intermediates and final products were purified and characterized by HPLC, UV, and ‘H-NMR. The deuterated internal standards of 9-HODE, 9R10R-trans-epoxy-11E-13R-hydroxyoctadecenoate, and the 9R,10S,13R-triol for LC-MS quantitative assays were prepared from [9,10,12,13-2H4]linoleic acid as described (34). The deuterated internal standards for assay of the corresponding 13-ketones of the epoxy-alcohol and triol were prepared by derivatization of the free acid with trideuterated methoxylamine hydrochloride CD3ONH2.HCl (CDN Isotopes).

Quantitative LC-MS analysis of oxidized linoleate-containing ceramides in marine epidermis. The epidermis of neonatal WT and Sdr9c7-/- pups was extracted with MeOH/CHCl3, and the lipids processed with minor changes from previous methods (34), as described in detail in Supplemental Methods. Briefly, after 3 washes with MeOH/CHCl3, the pooled lipid extract was chromatographed on an open-bed silica cartridge and the ceramide fraction subsequently treated with methoxylamine hydrochloride in pyridine to convert fatty acid keto groups to the methylxylene derivative. Deuterated internal standards (0.1 nmol, ~30 ng) were then added for analysis of 9-HODE, 9R10R-trans-epoxy-11E-13R-hydroxy-octadecenoate, 9R10R-trans-epoxy-11E-13R-keto-octadecenoate, 9R,10S,13R-dihydroxy-11E-13-keto-octadecenoate, and 9R,10S,13R-trihydroxy-11E-octadecenoate. Alkaline hydrolysis of the esterified lipids was followed by recovery of the oxidized linoleates using a reversed-phase Oasis cartridge (Waters), formation of the pentafluorobenzyl esters, and for analysis of the dihydroxy-13-keto- and trihydroxy-linoleates, conversion to the 9,10-dimethoxypropyl (DMP) acetamide derivative, as described previously in detail (34).

The PFB or PFB-DMP derivatives were analyzed as the M-PFB ions by APCI-LC-MS using a TSQ Vantage instrument (Thermo Fisher Scientific) with the APCI vaporizer temperature set to 500°C, and the capillary temperature set to 150°C. The HPLC used a Waters Alliance 2690 system and a Phenomenex Luna 5 μm silica column (25 × 0.2 cm) with a flow rate of 0.6 mL/min, and a solvent of hexane/isopropanol in the proportions 100:0.2 (vol/ vol) for analysis of 9-HODE (recorded at m/z 295 [d0] and m/z 299 [d4]), 9,10-epoxy-13-hydroxy-C18:1 (m/z 311 and m/z 315), 9,10-epoxy-13-methoxide-C18:1 (m/z 338 and m/z 341 [d3]), 9,10-dihydroxy DMP 13-methoxide (m/z 396 and m/z 399) and the proportions 100:1 (vol/vol) for analysis of linoleate triols (PFB, DMP derivative recorded at m/z 369 [d0] and m/z 373 [d4]). Quantitation of CerOS covalently bound to epidermal proteins was carried out essentially as previously described (10), as detailed in Supplemental Methods. The LC-MS analyses used an LTQ linear ion trap mass spectrometer (Thermo-Electron) equipped with an Ion Max APCI source and recording positive ions (m/z 700–900) in full scan mode, and a Phenomenex Luna 5 μm silica column with a solvent of hexane/isopropanol/glacial acetic acid, 90:10:0.1 (vol/vol/vol) at a flow rate of 0.6 mL/min, with retention time for CerOS of approximately 4 minutes.
A patient with lamellar ichthyosis. The patient was a 22-year-old Japanese woman, the fourth daughter born to nonrelated parents without any family history of similar disorders (Supplemental Figure 1D). At birth, she showed a collodion membrane on her entire body surface. Then, she presented with generalized ichthyosis. Examination revealed diffuse brown shiny scales on the trunk and extremities. She also had mild palmoplantar keratoderma (Figure 1A, Supplemental Figure 1, A and B). Her skin tends to be milder when she is in a high temperature and humid environment. Her hair, nails, and teeth were normal. She did not have any neurological symptoms or hearing loss. Her serum biochemistry showed the normal vitamin A level, 530 ng/mL (normal range, 431–1041 ng/mL).

Analysis of the patient’s stratum corneum lipid by tape stripping and LC-MS. To examine the ceramide species present in the stratum corneum, tape stripping was performed by pressing and stripping an adhesive acrylic film (465 no. 40; Teraoka Seisakusho) from the skin of the right upper arm and forearm of the patient and her parents. Samples were also taken from the same lesions of 8 normal controls (healthy women in their twenties or thirties) as controls. Five strips measuring 25 × 50 mm each were obtained from a single individual. Half of the samples were then subjected to LC-MS analysis to assess the levels of 11 major ceramide species (51-53) and 2 bound ceramide species. The strips were cut into half-strips, 25 × 15 mm in size: one for LC-MS analysis and the other for protein analysis. The lipids within the first half-stripe were dissolved in 2 mL chloroform/methanol/2-propanol (volume ratio: 10:45:45). N-heptadecanoyl-D-erythro-sphingosine (d18:1/17:0) (Avanti Polar Lipids) was added as an internal control, and its final concentration was 50 nmol/L. We confirmed the amount of endogenous d18:1/17:0 ceramide (NS_C35) in the stratum corneum (Supplemental Table 12). The results show that a small amount of endogenous d18:0/17:0 ceramide is present in the stratum corneum and, estimated from the peak area, the amounts of NS_C36, NS_C37, and NS_C38 are almost the same.

The amount of endogenous d18:1/17:0 ceramide against the added synthetic standard is about 0.7%. The ratio was calculated by the following formula: (peak area of the synthetic standard-free sample, 676) / (peak area of the synthetic standard-added sample, 98,023) × 100 = 0.69.

We quantified all ceramide species by calculating the relative sensitivity of chain lengths and types from an approximate expression. This lipid solution was subjected to reverse-phase LC-MS. The lipids within the first half-stripe were dissolved in 2 mL chloroform/methanol/2-propanol (volume ratio: 10:45:45). N-heptadecanoyl-D-erythro-sphingosine (d18:1/17:0) (Avanti Polar Lipids) was added as an internal control, and its final concentration was 50 nmol/L. We confirmed the amount of endogenous d18:1/17:0 ceramide (NS_C35) in the stratum corneum (Supplemental Table 12). The results show that a small amount of endogenous d18:0/17:0 ceramide is present in the stratum corneum and, estimated from the peak area, the amounts of NS_C35, NS_C34, NS_C35, NS_C36, and NS_C37 are almost the same.

The amount of endogenous d18:1/17:0 ceramide against the added synthetic standard is about 0.7%. The ratio was calculated by the following formula: (peak area of the synthetic standard-free sample, 676) / (peak area of the synthetic standard-added sample, 98,023) × 100 = 0.69.

We quantified all ceramide species by calculating the relative sensitivity of chain lengths and types from an approximate expression. This lipid solution was subjected to reverse-phase LC-MS. The system was an Agilent 6130 Series LC-MSD system equipped with a multi-ion source, ChemStation software, an Agilent 1260 Infinity Series LC (Agilent Technologies), and an L-column octadecysil (2.1 mm internal diameter × 150 mm; Chemicals Evaluation and Research Institute). Chromatographic separation of the lipids was achieved at a flow rate of 0.2 mL/minute using a mobile phase of binary gradient solvent system. Each ceramide species was detected by selected ion monitoring of m/z [M+acetate]– and HPLC retention times specific to ceramide species (Supplemental Table 13). In detail, phospholipids, sphingolipids, and fatty acids are detectable in the negative ion mode, although phospholipids are almost not included in the sebum and the stratum corneum intercellular lipids. The other lipids in the skin, such as triglycerides, wax esters, cholesterol esters, and squalene, are not detected in the negative ion mode. Ceramides and fatty acids can be completely separated according to their mass and polarity differences. Some groups of ceramide species (NH, AS, and NDS; AP, ADS, and AH; EODS and EOH) may have identical masses depending on the specific combinations of sphingolipids and fatty acids. However, they can be discriminated by their specific retention times of HPLC, according to the polarity differences (Supplemental Table 13). Soluble proteins were extracted from the other half-strip with a 0.1 mol/L NaOH-1% sodium dodecyl sulfate solution at 60°C for 150 minutes, followed by neutralization with HCl. The concentration of soluble proteins was determined using a BCA protein assay kit (Thermo Fisher Scientific).

Expression, purification, and assay of human and mouse SDR9C7.

cDNA of full-length human SDR9C7 was purchased from Kazusa Genome Technologies. The substitution c.826C>T (p.Arg276Cys) is a mutation in the ARCI patient of the present study, whereas the truncation c.658C>T (p.Arg220*) was a previously reported mutation in the patient with ARCI from another group (30). Human SDR9C7 proteins (WT, R276C and R220*) were expressed including an N-terminal FLAG tag in a silkworm-baculovirus system, ProCube (Sysmex Corporation) as described elsewhere (54). Expression constructs of the mouse Sdrr9c7 were synthesized by BioBasic, transferred into pET28b vector, and expressed in E. coli. This produced strong enzymatic activity in the bacterial lysate (100 μL lysate/mL completely metabolized 100 μM 13-HODE free acid in 10 minutes at 37°C); however, despite testing N-terminal and C-terminal His6 tags in the constructs, the activity was not captured on a nickel affinity column. Because of ester hydrolyase activity in the crude lysate, these preparations were of limited utility for analysis of esterified substrates.

Enzyme incubations with FLAG-tag purified SDR9C7 were conducted at room temperature in a total volume of 0.5 mL in 0.1M sodium phosphate pH 7.4 containing 1 mM NAD+, 100 μM substrate (e.g., epoxy-hydroxy free fatty acid or methyl ester), 0.1% polyoxyethylene tridecyl ether detergent (MilliporeSigma), and 1-2 μg enzyme. Rates of reaction were monitored by UV spectroscopy for appearance of
the NADH chromophore (\(\lambda_{max} 340\) nm, recorded for 10 minutes by repetitive scans at 1-minute intervals over the range 300–450 nm).

After continuing the incubation for 30 minutes at room temperature, enzymatic products were extracted with dichloromethane or using a 30 mg Oasis cartridge (Waters) with final elution using ethyl acetate or methanol. Initial screening of the products was conducted on an Agilent 1200 series HPLC system with the diode array detector set to monitor 205, 220, 235, and 270 nm. Reversed-phase HPLC used a Waters Symmetry C18 column (25 x 0.46 cm) with isocratic solvent systems of acetonitrile/water/glacial acetic acid adjusted from 80:20:0.01 (vol/vol/vol) to higher percentages of water depending on the polarity of the analytes, with a flow rate of 1 mL/min. Normal-phase HPLC used a Thompson Advantage silica column (25 x 0.46 cm) with solvent systems of hexane containing 0.5%-5% isopropanol, depending on the polarity of the analytes. Chiral HPLC used a Chiralpak AD column (15 x 0.2 cm or 25 x 0.46 cm) with a solvent system of hexane/EtOH/MeOH for epoxy-hydroxy methyl ester derivatives (10).

**Data availability.** The microarray data can be accessed at the GEO repository under the accession numbers GSE87682 (22) and GSE135643.

**Statistics.** Significance was determined by unpaired 2-tailed Student’s t test for normally distributed samples and using the nonparametric Mann-Whitney U test (2-tailed) for quantitative LC-MS analyses. A P value less than 0.05 was considered significant. All the data are mean ± SEM (error bar).

**Study approval.** This study was approved by the ethics committee of the Nagoya University Graduate School of Medicine. All studies were conducted according to the Declaration of Helsinki Principles. Animal care and all experimental procedures were approved by the Animal Experiment Committee, Graduate School of Medicine, Nagoya University, and were conducted according to the Regulations on Animal Experiments of Nagoya University.

**Author contributions**

TT, TH, ARB, and MA designed the research studies. TT, TH, Y Miyasaka, AK, YO, K Tanahashi, HT, K Tanaka, MWC, WEB, JJ, TO, ARB, and MA conducted experiments. TT, TH, AK, YO, and K Tanahashi acquired data. TT, TH, AK, YO, K Tanahashi, JJ, ARB, and MA analyzed data. TT, ST, and CM collected clinical samples and information. TT, TH, ARB, and MA wrote the manuscript. DW, MK, and Y Muro helped write the paper.

**Acknowledgments**

We thank the staff at the Division of Experimental Animals, Nagoya University Graduate School of Medicine, for their technical support. We also thank Yasumasa Nishito, Haruka Ozeki, Mitsuko Kobayashi, and Yuka Terashita for their valuable assistance. This work was supported by funding from Advanced Research and Development Programs for Medical Innovation (AMED-CREST) (19gm091002h0105 to MA and 19gm0910002h0205 to TH) from the Japan Agency for Medical Research and Development (AMED). This work was also supported by a Grant-in-Aid for Scientific Research (B) (18H02832 to MA) and by a Grant-in-Aid for Young Scientists (18K16058 to TT) from the Japan Society for the Promotion of Science (JSPS). This investigation was supported in part by The Mochida Memorial Foundation for Medical and Pharmaceutical Research, The Uehara Memorial Foundation, and The Kanae Foundation for the Promotion of Medical Science. ARB acknowledges support from the Department of Pharmacology, Vanderbilt University, and thanks James Weiny for technical assistance with the analysis of recombinant SDR9C7.

Address correspondence to: Takuya Takeichi or Masashi Akiyama, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. Phone: +81.52.744.2314; Email: takeichi@med.nagoya-u.ac.jp (T. Takeichi); makiyama@med.nagoya-u.ac.jp (M. Akiyama). Or to: Alan R. Brash, Department of Pharmacology, RRB Room 510, Vanderbilt University, Nashville, Tennessee 37232, USA. Phone: 615.322.3015; Email: alan.brash@vanderbilt.edu.

18. Kalinin AE, Kajava AV, Steinitz PM. Epidermal barrier function: assembly and structural fea-


